Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Kamada ( (IL:KMDA) ).
On December 10, 2025, Kamada Ltd. held its Annual General Meeting of Shareholders, where all proposed resolutions were approved. These included the re-election of the company’s seven directors, granting options to the CEO, adopting an amended compensation policy, and approving amendments to the company’s Articles of Association to allow for indemnification and insurance of directors and officers. Additionally, the re-appointment of Kost Forer Gabbay & Kasierer as the company’s independent auditors was ratified. These decisions are expected to strengthen Kamada’s corporate governance and operational framework, potentially impacting its market position and stakeholder relations positively.
The most recent analyst rating on (IL:KMDA) stock is a Buy with a ILs13.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.
More about Kamada
Kamada Ltd. operates in the biopharmaceutical industry, focusing on the development, production, and marketing of specialty plasma-derived protein therapeutics. The company is based in Rehovot, Israel, and is known for its expertise in the production of plasma-derived protein therapeutics.
Average Trading Volume: 88,009
Technical Sentiment Signal: Hold
Current Market Cap: ILs1.26B
Find detailed analytics on KMDA stock on TipRanks’ Stock Analysis page.